Five years after her type 2 diabetes diagnosis, Deb Biller was running out of options. Biller knew that her glucose levels had been rising at each yearly check-up with her primary care physician (PCP) ...

The tech entrepreneur has said he purchased the bills from the U.S. Bureau of Engraving and Printing and customized them at a print shop Charlotte Phillipp is a Weekend Writer-Reporter at PEOPLE. She ...

As GLP-1s grow in popularity, more Americans are rethinking weight loss in the new year KIRKLAND, Wash, Dec. 19, 2025 /PRNewswire/ -- A new survey from Sunlight.com finds that interest in GLP-1 ...

Few medications have had such a meteoric rise as semaglutide (Ozempic, Wegovy) and tirzepatide (Zepbound), the GLP-1-based treatments for obesity that have captivated society and quickly become ...

Editor’s note: “Behind the News” is the product of Sun staff assisted by the Sun’s AI lab, which includes a variety of tools such as Anthropic’s Claude, Perplexity AI, Google Gemini and ChatGPT. Dewey ...

Every week for the duration of the 2025 regular season, USA TODAY Sports will provide timely updates to the NFL's ever-evolving playoff picture − typically starting Sunday afternoon and then moving ...

While insurance generally covers GLP-1s for the treatment of type 2 diabetes — though sometimes with limitations, depending on the insurance plan — far fewer insurance companies cover the medication ...

If your doctor recommended you start taking a glucagon-like peptide-1 (GLP-1) receptor agonist like semaglutide to help manage your metabolic dysfunction-associated steatohepatitis (MASH), you likely ...

Glucagon-like peptide 1 (GLP-1) receptor agonists offer promise in weight and cardiovascular risk reduction, but their use must complement—not replace—lifestyle interventions within a holistic, ...

Discover what star athletes and actors on Zepbound, Mounjaro, Ozempic, and Wegovy have to say about their experiences on these game-changing medications.